600276 Jiangsu Hengrui Pharmaceuticals
- 50.48
- +1.26+2.56%
Jiangsu Hengrui Pharmaceuticals News
Hengrui Pharmaceutical\'s indicative notice on the re-submission of the biological product licensing application for injectable carelizumab to be accepted by the FDA
Hengrui Pharmaceutical\'s indicative announcement on acceptance of drug marketing license applications
Hengrui Pharmaceutical\'s announcement on the inclusion of drugs in the list of breakthrough treatment varieties
Hengrui Pharmaceutical\'s indicative announcement on acceptance of drug marketing license applications
Hengrui Pharmaceutical: Hengrui Pharmaceutical\'s announcement on the progress of share repurchases
Hengrui Pharmaceutical\'s indicative announcement on acceptance of drug marketing license applications
Hengrui Pharmaceutical\'s indicative announcement on acceptance of drug marketing license applications
Hengrui Pharmaceutical\'s Announcement on the Inclusion of Drugs in the List of Proposed Breakthrough Therapeutics
Hengrui Pharmaceutical 2024 Employee Stock Ownership Plan
Legal Opinion of Hengrui Pharmaceutical\'s 2024 First Extraordinary General Meeting of Shareholders
Announcement of Resolutions of Hengrui Pharmaceutical\'s 2024 First Extraordinary General Meeting of Shareholders
Hengrui Pharmaceutical\'s indicative announcement on acceptance of drug marketing license applications
Hengrui Pharmaceutical 2024 First Extraordinary Shareholders\' Meeting Meeting Information
Announcement from Jiangsu Hengrui Pharmaceuticals regarding the resignation of company executives.
General Manager's Work Rules (Revised in 2024)
Rules of Procedure for Board Meetings (Revised in 2024)
Jiangsu Hengrui Pharmaceuticals Employee Stock Ownership Plan (Draft) for 2024
Jiangsu Hengrui Pharmaceuticals 2024 Employee Stock Ownership Plan (Draft) Summary
Amendment to the Articles of Association of Jiangsu Hengrui Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Bylaws (Revised 2024)
Analysis
Price Target
No Data
No Data